Parliamentary panel tells Centre to promote cheaper, domestically produced COVID-19 medicines
Cutting across party lines, the committee members questioned why expensive medicines were often being recommended for COVID-19 treatment.
New Delhi: A Parliamentary panel told senior government officials on Wednesday to promote cheaper and easily available domestic-made medicines for COVID-19, and check recommendation and cap prices of expensive medicines pushed by pharma companies, sources said.
During a meeting of Parliamentary Standing Committee on Home Affairs, members also demanded that the maximum price of COVID-19 medicines be capped, they said.
Home Secretary Ajay Bhalla, Joint Secretary in Health Ministry Lav Agarwal and other officials were present in the meeting of the standing committee on home affairs chaired by Congress leader Anand Sharma.
Cutting across party lines, the committee members questioned why expensive medicines were often being recommended for COVID-19 treatment, sources in the panel said.
The committee members expressed concern over black marketing of medicines.
Naming three cheaper and easily available medicines, the committee members questioned why are they not being promoted despite they being equally effective.
The guidelines issued last month had allowed reopening of cinema halls, swimming pools for sports training and gatherings with restrictions
The health ministry said that India reported 10 lakh recoveries in a span of 13 days, taking the country’s recovery rate to 90.62 percent
COVID-19 treatment: CBD derived from cannabis may help reverse lung damage caused by cytokine storm, find studies
When CBD was administered to mice with acute respiratory distress syndrome (ARDS) caused by the cytokine storm during COVID-19 infection, the level of apelin, which helps maintain blood pressure and also reduces inflammation along with ACE-2, also increased thus improving blood and oxygen flow